Pakdaman H, Sahraian M A, Fallah A, Pakdaman R, Ghareghozli K, Ghafarpour M, Rahimian E, Shirani A
Department of Neurology, Shahid Beheshti University of Medical Sciences, Loghman Haskim Street, Tehran 789065, Iran.
Acta Neurol Scand. 2007 Jun;115(6):429-31. doi: 10.1111/j.1600-0404.2007.00813.x.
A new treatment approach to multiple sclerosis (MS) is the initiation of interferon therapy in the early phase of the disease when a patient presents with clinically isolated syndrome.
The goal of this study was to assess the effect of early treatment on the risk of conversion to clinically definite MS in Iranian patients.
Eligible patients had presented with a first episode of neurological dysfunction suggesting MS within the previous 3 months and had abnormal brain magnetic resonance imaging (MRI). Patients were randomly assigned to receive intramuscular interferon beta 1a 30 mug or placebo once a week for 3 years.
Of the 217 patients randomized, 202 patients completed the study; 104 received Avonex and 98 received placebo. Fewer patients converted to clinically definite multiple sclerosis in the treated group than in the placebo group during the study (36.6% vs 58.2%, P < 0.003). The number of active T2-weighted MRI lesions was significantly lower in the treated group.
The results of our study, which are consistent with those from western studies, show that treatment at an early stage of MS delays conversion to definite MS and has positive effects on MRI outcomes.
多发性硬化症（MS）的一种新治疗方法是在疾病早期，当患者出现临床孤立综合征时开始使用干扰素治疗。
本研究的目的是评估早期治疗对伊朗患者转化为临床确诊MS风险的影响。
符合条件的患者在过去3个月内首次出现提示MS的神经功能障碍发作，且脑磁共振成像（MRI）异常。患者被随机分配接受每周一次30μg肌肉注射干扰素β-1a或安慰剂，持续3年。
在随机分组的217例患者中，202例完成了研究；104例接受了阿沃尼克斯，98例接受了安慰剂。在研究期间，治疗组转化为临床确诊多发性硬化症的患者少于安慰剂组（36.6%对58.2%，P<0.003）。治疗组中T2加权MRI活性病变数量显著更低。
我们的研究结果与西方研究结果一致，表明MS早期治疗可延迟转化为确诊MS，并对MRI结果有积极影响。
